Drug Profile
LGT 209
Alternative Names: Anti-PCSK9 monoclonal antibody - Novartis; LGT209; NVP-LGT 209Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 24 Aug 2016 Cyon Therapeutics in-licenses LGT 209 for the use systemic inflammatory response syndrome and the prevention and treatment of sepsis from Novartis
- 24 Aug 2016 Cyon Therapeutics plans a phase II trial for Sepsis in
- 23 Jan 2013 Discontinued - Phase-II for Hypercholesterolaemia in USA (IV, SC)